Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

teva parenteral medicines, inc. - haloperidol decanoate (unii: ac20pj4101) (haloperidol - unii:j6292f8l3d) - haloperidol 50 mg in 1 ml - haloperidol decanoate injection 50 mg/ml and haloperidol decanoate injection 100 mg/ml are indicated for the treatment of schizophrenic patients who require prolonged parenteral antipsychotic therapy. since the pharmacologic and clinical actions of haloperidol decanoate injection 50 mg/ml and haloperidol decanoate injection 100 mg/ml are attributed to haloperidol as the active medication, contraindications, warnings, and additional information are those of haloperidol, modified only to reflect the prolonged action. haloperidol is contraindicated in severe toxic central nervous system depression or comatose states from any cause and in individuals who are hypersensitive to this drug or have parkinson's disease.

Israel - Inggeris - Ministry of Health

unipharm trading ltd, israel - haloperidol as decanoate - solution for injection - haloperidol as decanoate 100 mg/ml - haloperidol - haloperidol - indicated for the maintenance treatment of schizophrenia and schizoaffective disorder in adult patients currently stabilized with oral haloperidol..

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

janssen-cilag ltd - haloperidol decanoate - solution for injection - 50 milligram(s)/millilitre - butyrophenone derivatives; haloperidol

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

janssen sciences ireland uc - haloperidol - solution for injection - 100 milligram(s)/millilitre - butyrophenone derivatives; haloperidol

Malta - Inggeris - Medicines Authority

syri pharma limited floor 0 1 wml, 1 windmill lane dublin 2, d02 f206, ireland - haloperidol - oral solution - haloperidol 1 mg/ml - psycholeptics

Singapura - Inggeris - HSA (Health Sciences Authority)

duopharma (singapore) pte ltd - haloperidol - injection - 5 mg/ml - haloperidol 5 mg/ml

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

somerset therapeutics, llc - haloperidol decanoate (unii: ac20pj4101) (haloperidol - unii:j6292f8l3d) - haloperidol decanoate injection, 50 mg (base)/ml and haloperidol decanoate injection, 100 mg (base)/ml are indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy. since the pharmacologic and clinical actions of haloperidol decanoate injection, 50 mg /ml and haloperidol decanoate injection, 100 mg/ml are attributed to haloperidol, usp as the active medication, contraindications, warnings, and additional information are those of haloperidol, usp, modified only to reflect the prolonged action.   haloperidol is contraindicated in patients with: - severe toxic central nervous system depression or comatose states from any cause. - hypersensitivity to this drug – hypersensitivity reactions have included anaphylactic reaction and angioedema (see warnings, hypersensitivity reactions and adverse reactions). - parkinson's disease (see warnings, neurological adverse reactions in patients with parkinson's disease or dementia with lewy bodies). - dementia with lewy bodies (see warnings, neurological adverse reactions in patients with parkinson's disease or dementia with lewy bodies).

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - haloperidol decanoate (unii: ac20pj4101) (haloperidol - unii:j6292f8l3d) - haloperidol decanoate injection is indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy. since the pharmacologic and clinical actions of haloperidol decanoate are attributed to haloperidol as the active medication, contraindications, warnings, and additional information are those of haloperidol, modified only to reflect the prolonged action. haloperidol is contraindicated in patients with: - severe toxic central nervous system depression or comatose states from any cause. - hypersensitivity to this drug – hypersensitivity reactions have included anaphylactic reaction and angioedema (see warnings, hypersensitivity reactions and adverse reactions). - parkinson's disease (see warnings, neurological adverse reactions in patients with parkinson's disease or dementia with lewy bodies). - dementia with lewy bodies (see warnings, neurological adverse reactions in patients with parkinson's disease or dementia with lewy

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

remedyrepack inc. - haloperidol decanoate (unii: ac20pj4101) (haloperidol - unii:j6292f8l3d) - haloperidol decanoate injection, 50 mg (base)/ml and haloperidol decanoate injection, 100 mg (base)/ml are indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy. since the pharmacologic and clinical actions of haloperidol decanoate injection, 50 mg /ml and haloperidol decanoate injection, 100 mg/ml are attributed to haloperidol, usp as the active medication, contraindications, warnings, and additional information are those of haloperidol, usp, modified only to reflect the prolonged action.   haloperidol is contraindicated in patients with: -   severe toxic central nervous system depression or comatose states from any cause. -   hypersensitivity to this drug – hypersensitivity reactions have included anaphylactic reaction and angioedema (see warnings, hypersensitivity reactions and adverse reactions). -   parkinson's disease (see warnings, neurological adverse reactions in patients with parkinson's disease or dementia with lewy bodies). -   dementia w

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

remedyrepack inc. - haloperidol decanoate (unii: ac20pj4101) (haloperidol - unii:j6292f8l3d) - haloperidol decanoate injection, 50 mg (base)/ml and haloperidol decanoate injection, 100 mg (base)/ml are indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy. since the pharmacologic and clinical actions of haloperidol decanoate injection, 50 mg /ml and haloperidol decanoate injection, 100 mg/ml are attributed to haloperidol, usp as the active medication, contraindications, warnings, and additional information are those of haloperidol, usp, modified only to reflect the prolonged action.   haloperidol is contraindicated in patients with: - severe toxic central nervous system depression or comatose states from any cause. - hypersensitivity to this drug – hypersensitivity reactions have included anaphylactic reaction and angioedema (see warnings, hypersensitivity reactions and adverse reactions). - parkinson's disease (see warnings, neurological adverse reactions in patients with parkinson's disease or dementia with lewy bodies). - dementia with lewy bodies (see warnings, neurological adverse reactions in patients with parkinson's disease or dementia with lewy bodies).